Interleukin 10 and transforming growth factor‐beta 1 plasma levels in atopic dogs before and during immunotherapy

Martini, F.; Rostaher, Ana; Favrot, Claude; Fischer, Nina

doi:10.1002/vetr.1270

Cited by 4 publications

(11 citation statements)

References 54 publications

(155 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cytokine is secreted by Tregs but also stimulates the differentiation of Th0 cells towards Tregs. Although in the study by Martini and coworkers [32], no statistically significant difference in plasma levels of TGF-β was observed in AD dogs during subcutaneous immunotherapy (SCIT), a tendency of decreasing concentration of this cytokine during therapy could be noted, which is similar to our results.…”

Section: Discussionsupporting

confidence: 91%

“…In the presented study, the average plasma level of IL-10 was similar in cAD patients during ASIT and before therapy and did not differ from that of the healthy dogs. Further, Martini and coworkers [ 32 ] did not show changes in the plasma level of IL-10 during SCIT after 3, 6 and 12 months of application. However, when looking at the results of individual patients in our study, it can be noted that in three dogs, the level of IL-10 increased after 6 months of treatment compared to before therapy ( Figure S2F ).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Cytokine and Lymphocyte Profiles in Dogs with Atopic Dermatitis after Allergen-Specific Immunotherapy

et al. 2022

View full text Add to dashboard Cite

Canine atopic dermatitis (cAD) is a chronic and recurrent inflammatory and pruritic skin disease in dogs. Currently, allergen-specific immunotherapy (ASIT) is the only identified disease-modifying intervention for allergic diseases. It decreases the symptoms triggered by allergens and prevents recurrence of the disease in the long-term. The aim of our research was to determine how immunotherapy changes the proportion of lymphocyte subsets in dog peripheral blood and the levels of cytokines secreted by these cells during therapy. ASIT was applied for 6 months. Blood samples for further analyses were collected from patients in the third and sixth month of immunotherapy. Six out of seven dogs receiving ASIT showed a positive effect. A reduction in cytokine levels (IL-13, TNF-α) in peripheral blood of cAD patients and changes in the number of specific T cell subpopulations—reduction of Tc cells (CD8+) and increase of activated T cells (CD3+CD25+)—confirmed the beneficial effect of the applied ASIT. In addition, a significantly higher percentage of Treg cells (CD4+CD25+FOXP3+) was noted in cAD patients before treatment compared to healthy dogs. After 3 months of therapy, the percentage of Tregs significantly decreased, and after 6 months, it increased significantly again.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 98%

Cytokine and Lymphocyte Profiles in Dogs with Atopic Dermatitis after Allergen-Specific Immunotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…7 Our results reflect the findings of a recent study analysing IL-10 and TGF-1 in dogs treated with AIT that did not find significant differences between healthy dogs and atopic dogs, and pre-and post-12 months AIT treatment, except in the intralymphatic immunotherapy group. 47 Similar to the veterinary field, results (reviewed) are controversial on the effect of AIT on Treg cell numbers and cytokine levels in atopic humans. 14 The differences in Treg cell numbers between healthy and atopic dogs vary between studies, with most studies showing increased numbers of Treg cells in atopic compared with healthy dogs.…”

Section: Discussionmentioning

confidence: 99%

“…This is not unusual as several previous studies showed canine serum IL-10 to be highly variable and often reported to be very low or undetectable. 14,47,56,57 We used a validated canine IL-10 Quantikine ELISA (R&D Systems), the performance of which in various canine studies over the past years has been reviewed recently. 47 Interestingly, it appears that older studies that employed this assay detected higher IL-10 values than those published more recently.…”

Section: Discussionmentioning

confidence: 99%

“…14,47,56,57 We used a validated canine IL-10 Quantikine ELISA (R&D Systems), the performance of which in various canine studies over the past years has been reviewed recently. 47 Interestingly, it appears that older studies that employed this assay detected higher IL-10 values than those published more recently. 7,47 It has been suggested in a review that a change in the protocol and/or the kit composition could be responsible for these variations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T‐cells, IL‐10 and TGF‐β, in dogs with atopic dermatitis

Herrmann

Mamo

Holmes

et al. 2022

Veterinary Dermatology

View full text Add to dashboard Cite

Background: Atopic dogs often are managed with allergen-specific immunotherapy (AIT) and concurrent dosages of ciclosporin (CSA) or oclacitinib to alleviate their clinical signs. Both drugs might affect proper tolerance induction by inhibiting regulatory T-cell (Treg) induction. Hypothesis/Objectives: We evaluated Treg cell numbers and serum interleukin (IL)-10 and transforming growth factor-beta (TGFβ)1 levels in dogs diagnosed with atopic dermatitis (AD) and successfully treated with either CSA or oclacitinib for nine or more months. Animals: We included 15 dogs receiving oclacitinib, 14 dogs treated with CSA, 15 healthy dogs, 13 dogs with untreated moderate-to-severe AD and 15 atopic dogs controlled with AIT. Materials and Methods: Peripheral blood CD4+CD25+FOXP3+ T-cell percentages were determined using flow cytometry. Serum concentrations of IL-10 and TGF-β1 were measured by enzyme-linked immunosorbent assay. Results: The percentage of Treg cells in the CSA group was significantly lower in comparison with the healthy group (p = 0.0003), the nontreated AD group (p = 0.0056) or the AIT group (p = 0.0186). There was no significant difference in Treg cell percentages between the CSA and oclacitinib groups, nor between the oclacitinib and the healthy, nontreated AD or AIT-treated dogs. No significant differences were detected in IL-10 and TGF-β1 serum concentrations between the five groups. Conclusions and Clinical Relevance: Lower Treg cell percentages in the CSA-treated dogs suggest an impact of this drug on this cell population; however, it does not necessarily mean that it diminishes tolerance. Functionality and cytokine production may be more important than the number of Treg cells. Further studies evaluating the treatment outcome of dogs receiving AIT and concurrent drugs are needed to show clinical relevance.

show abstract

Update on the role of cytokines and chemokines in canine atopic dermatitis

Tamamoto-Mochizuki

Santoro

Saridomichelakis

et al. 2023

Veterinary Dermatology

View full text Add to dashboard Cite

BackgroundCytokines and chemokines play central roles in the pathogenesis of canine atopic dermatitis (cAD). Numerous studies have been published and provide new insights into their roles in cAD.ObjectivesTo summarise the research updates on the role of cytokines and chemokines in the pathogenesis of cAD since the last review by the International Committee on Allergic Diseases of Animals in 2015.Material and MethodsOnline citation databases, abstracts and proceedings from international meetings on cytokines and chemokines relevant to cAD that had been published between 2015 and 2022 were reviewed.ResultsAdvances in technologies have allowed the simultaneous analysis of a broader range of cytokines and chemokines, which revealed an upregulation of a multipolar immunological axis (Th1, Th2, Th17 and Th22) in cAD. Most studies focused on specific cytokines, which were proposed as potential novel biomarkers and/or therapeutic targets for cAD, such as interleukin‐31. Most other cytokines and chemokines had inconsistent results, perhaps as a consequence of their varied involvement in the pathogenesis of different endotypes of cAD.Conclusions and Clinical RelevanceInconsistent results for many cytokines and chemokines illustrate the difficulty of studying the complex cytokine and chemokine networks in cAD, and highlight the need for more comprehensive and structured studies in the future.

show abstract

Interleukin 10 and transforming growth factor‐beta 1 plasma levels in atopic dogs before and during immunotherapy

Cited by 4 publications

References 54 publications

Cytokine and Lymphocyte Profiles in Dogs with Atopic Dermatitis after Allergen-Specific Immunotherapy

Cytokine and Lymphocyte Profiles in Dogs with Atopic Dermatitis after Allergen-Specific Immunotherapy

Long‐term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T‐cells, IL‐10 and TGF‐β, in dogs with atopic dermatitis

Update on the role of cytokines and chemokines in canine atopic dermatitis

Contact Info

Product

Resources

About